Coverage
-
April 17, 2017
A putative class of investors in Amicus Therapeutics Inc. who said the company's misleading statements about their interaction with the U.S. Food and Drug Administration amounted to securities fraud asked a New Jersey federal court on Friday to approve a $3.75 million settlement that would end the litigation before the court even considered dismissal.
1 other articles on this case.
View all »